ImmunityBio Inc. Common Stock (IBRX)
Stock · NASDAQ · Health Care
$9.18as of 10/16/2026
Price chart
Active signals
IBRX Signal Track Record
How signals performed across all stocks →What IBRX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -8.2% | 37% | October 2, 2026 |
| Bollinger Band Breakout | 26 | -13.4% | 35% | September 22, 2026 |
| Bollinger Band Breakdown | 18 | -3.4% | 44% | March 30, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -3.3% | 43% | September 18, 2025 |
| Any 20-session window (baseline) | -0.6% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The com…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 684
- Website
- immunitybio.com/
Fundamentals
- 1-day range
- $9.35$10.46
- Market cap
- $7.76B
- P/E (trailing)
- —
- P/E (forward)
- -70.79
- EPS (trailing)
- $-0.97
- Dividend yield
- —
- Beta
- 0.17
- Avg. volume
- 10.51M
How ImmunityBio Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
ImmunityBio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
- TWSTTwist Bioscience Corporation Common Stock$132.75▼ 8.13%Market cap $6.84BP/E —$23.3$219.71
- KYMRKymera Therapeutics Inc. Common Stock$104.78▼ 3.11%Market cap $8.75BP/E —$55.26$130.05
- CGONCG Oncology Inc. Common stock$59.85▼ 3.25%Market cap $6.60BP/E —$35.8$80.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
| TWST Twist Bioscience Corporation Common Stock | $6.84B | — | $132.75 | ▼ 8.13% | $23.3$219.71 |
| KYMR Kymera Therapeutics Inc. Common Stock | $8.75B | — | $104.78 | ▼ 3.11% | $55.26$130.05 |
| CGON CG Oncology Inc. Common stock | $6.60B | — | $59.85 | ▼ 3.25% | $35.8$80.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ImmunityBio Stock Jumps: What's Going On?Benzinga · 10/2/2026
- SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 SpotYahoo · 10/2/2026
- IBRX Stock Racks Up 3 Straight Quarterly Wins: Q3 Filings Reveal BlackRock Closing In On Vanguard With A Bigger BetYahoo · 10/1/2026
- IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 MonthsYahoo · 9/30/2026
- A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)Yahoo · 9/30/2026
- Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?Yahoo · 9/30/2026
- ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%Yahoo · 9/23/2026
- Could IBRX Be A Tokenized Stock? Founder’s Tease Sends ImmunityBio Traders Into Speculation ModeYahoo · 9/21/2026
Insider Activity
Insider Actions →- Cheryl Cohen · July 2, 2026 · Option Exercise56.0K @ $2.98
- Cheryl Cohen · July 2, 2026 · Sale131.2K @ $9.5
- Christobel Selecky · July 1, 2026 · Option Exercise35.1K @ $2.98
- Christobel Selecky · July 1, 2026 · Sale159.5K @ $9.02
- Christobel Selecky · July 1, 2026 · Option Exercise124.4K @ $2.99
- Christobel Selecky · June 30, 2026 · Option Exercise300 @ $2.99
- Christobel Selecky · June 30, 2026 · Option Exercise700 @ $2.98
- Christobel Selecky · June 30, 2026 · Sale1.0K @ $9
- Christobel Selecky · June 29, 2026 · Option Exercise30.0K @ $2.84
- Christobel Selecky · June 29, 2026 · Option Exercise33.5K @ $2.99
- Christobel Selecky · June 29, 2026 · Option Exercise32.2K @ $2.98
- Christobel Selecky · June 29, 2026 · Sale95.7K @ $9.01
- Barry J. Simon · June 24, 2026 · Sale25.0K @ $7.88
- Christobel Selecky · June 9, 2026 · Grant65.6K
- MAXWELL LINDA · June 9, 2026 · Grant65.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 182.70M
- Total value held
- $1.35B
- Institutional holders
- 386
- Unknown26.35M
- Unknown17.71M
- Unknown15.13M
- Unknown12.57M
- Unknown8.70M
- Unknown8.03M
- Unknown5.14M
- Unknown4.39M
- Unknown4.34M
- Unknown4.02M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
IBRX Posts Best Week In 7 Months On Trump Cancer Panel News
ImmunityBio shares recorded their strongest week in over seven months, driven by reports that a member of Trump's cancer panel supports the company's Anktiva drug. This positive news coincided with the stock breaking through key resistance levels. While the recent surge has lifted the price significantly, the stock remains within its 52-week range of $1.95 to $12.43.
IBRX Posts Best Week In 7 Months On Trump Cancer Panel News. ImmunityBio shares recorded their strongest week in over seven months, driven by reports that a member of Trump's cancer panel supports the company's Anktiva drug. This positive news coincided with the stock breaking through key resistance levels. While the recent surge has lifted the price significantly, the stock remains within its 52-week range of $1.95 to $12.43.